Podcast episode
The promise of AI in life sciences and healthcare
Ideas to Innovation - Season Three
Podcast episode
Ideas to Innovation - Season Three
Artificial intelligence is all around us and it’s revolutionizing our world in many ways. In life sciences and healthcare, AI-powered technologies are instrumental in tasks such as diagnostics, precision medicine and even robotic surgery. And the transformative aspect of generative AI is already being felt in areas such as pharmaceutical research, epidemiology and telemedicine. There are projections that the global market for AI in life sciences and healthcare will be $6.7 billion USD by 2030. What is driving such remarkable growth and how rosy is this picture?
Joining us at the start of a new season three of the “Ideas to Innovation” podcast from Clarivate is Henry Levy, who has plenty to say about AI and what it will and won’t enable us to achieve. Henry joined Clarivate earlier this year as President, Life Sciences and Healthcare (LS&H). He leads the teams focused on developing solutions that enable life sciences and healthcare companies and providers to create a healthier tomorrow by connecting them to transformative intelligence and data technology to improve patient lives. With more than 25 years of experience, Henry is the author of multiple articles on drug development and tech trends and a frequent speaker at industry forums. He holds a bachelor’s degree in bioengineering from the University of Pennsylvania.
Henry Levy joined Clarivate in May 2023 as President, Life Sciences & Healthcare (LS&H). He leads the teams focused on developing solutions that enable life sciences and healthcare companies and providers to create a heathier tomorrow by connecting them to transformative intelligence and data technology to improve patient lives. With over 25 years of experience, Henry is the author of multiple articles on drug development and technology trends and a frequent speaker at industry forums. Prior to Clarivate, Henry held several roles at Veeva Systems, including Chief Strategy Officer, General Manager for the Clinical Data Management product suite and, most recently, President, Global R&D and Quality. Previously, he was Chief Commercial Officer for PPD, where he defined new models for biopharmaceutical companies to partner with contract research organizations to drive down costs and improve the speed of drug development. Before that, he led Accenture’s global life sciences R&D practice, where he helped 90% of the top 20 biopharmaceutical companies improve through consulting, technology and outsourcing solutions. He holds a bachelor’s degree in bioengineering from the University of Pennsylvania.